Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Background: Natalizumab (NAT) is a high-efficacy treatment for relapsing remitting multiple sclerosis (RRMS). However, it is associated with an increased risk of progressive multifocal leukoencephalopathy that sometimes requires treatment cessation with a risk of returning disease activity. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Proschmann, Undine, Inojosa, Hernan, Akgün, Katja, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079654/
https://www.ncbi.nlm.nih.gov/pubmed/33935948
http://dx.doi.org/10.3389/fneur.2021.650530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079654/
https://www.ncbi.nlm.nih.gov/pubmed/33935948
http://dx.doi.org/10.3389/fneur.2021.650530

Ejemplares similares